ReviewWorld journal of gastroenterology2015
Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends.Frontiers in immunology · 2026Pooled it
- Nanomaterials and exercise interventions: A synergistic approach for atherosclerosis therapy (Review).International journal of molecular medicine · 2026Review
- Targeted-Immunomodulatory Nanomedicines for the Treatment of Autoimmune Diseases via Multiple Administration Routes.International journal of nanomedicine · 2025Review
- Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends.Frontiers in pharmacology · 2024Article
- Plant-Derived Exosomes as a Drug-Delivery Approach for the Treatment of Inflammatory Bowel Disease and Colitis-Associated Cancer.Pharmaceutics · 2022Review
- Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting.Pharmaceutics · 2022Article
- Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.Pharmaceutics · 2021Review
- Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.Advances in experimental medicine and biology · 2021Article
- Nanozymes Regulate Redox Homeostasis in ROS-Related Inflammation.Frontiers in chemistry · 2021Review
- Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.Advanced healthcare materials · 2020Article
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.Inflammatory bowel diseases · 2019Review
- Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease.Theranostics · 2019Article
- Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.International journal of nanomedicine · 2019Review
- Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.Molecules (Basel, Switzerland) · 2018Review
- Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.Frontiers in pediatrics · 2018Review
- Modulating the immune system through nanotechnology.Seminars in immunology · 2017Review
- Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in anWorld journal of gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease and ulcerative colitis are two important categories of human inflammatory bowel disease (IBD). Because the precise mechanisms of the inflammation and immune responses in IBD have not been fully elucidated, the treatment of IBD primarily aims to inhibit the pathogenic factors of the inflammatory cascade. Inconsistencies exist regarding the response and side effects of the drugs that are currently used to treat IBD. Recent studies have suggested that the use of nanomedicine might be advantageous for the treatment of intestinal inflammation because nano-sized molecules can effectively penetrate epithelial and inflammatory cells. We reviewed nanomedicine treatments, such as the use of small interfering RNAs, antisense oligonucleotides, and anti-inflammatory molecules with delivery systems in experimental colitis models and clinical trials for IBD based on a systematic search. The efficacy and usefulness of the treatments reviewed in this manuscript have been demonstrated in experimental colitis models and clinical trials using various types of nanomedicine. Nanomedicine is expected to become a new therapeutic approach to the treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.